Dr. Margaret Jorgensen joined HTANALYSTS in March 2013 and has over 25 years’ experience in assessing the best available evidence to inform health policy in the medical research, pharmaceutical and biotechnology industries. 

Dr. Margaret Jorgensen joined HTANALYSTS in March 2013 and has over 25 years’ experience in assessing the best available evidence to inform health policy in the medical research, pharmaceutical and biotechnology industries.  

At HTANALYSTS, Margaret’s focus is the development of clinical practice guidelines and the design and conduct of evidence reviews to reviews to support decision-making. She has conducted well over 50 rigorous systematic reviews of public health interest and contributed to numerous published guidelines. Margaret also provides strategic advice on methodology, consults with government, clinical and academic stakeholders to gain clinical insights, and was an evaluator on behalf of MSAC for the Department of Health & Ageing. 

Prior to joining HTANALYSTS, Dr. Jorgensen provided key stakeholders such as the Bill & Melinda Gates Foundation, the World Bank, and the International AIDS Vaccine Initiative with evidence-based research to support policy decisions for neglected diseases. Dr. Jorgensen also has prior experience managing late-phase clinical trials across several geographic regions and providing industry and non-industry clients with in-depth research and competitive intelligence as to the trends, emerging developments, and market potential of drugs & vaccines for commercial and neglected disease markets.  

Margaret obtained her a Bachelor of Medical Science (Hons) degree from University of Sydney, completed her PhD in molecular biology at The University of NSW and received postdoctoral training at Harvard T.H. Chan School of Public Health. Dr Jorgensen a has since published several articles in peer-reviewed journals and received external training in GRADE methodology, biostatistics, health technology assessment and project management.